{"id":26341,"date":"2014-06-19T09:44:42","date_gmt":"2014-06-19T13:44:42","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=26341"},"modified":"2014-06-19T09:44:42","modified_gmt":"2014-06-19T13:44:42","slug":"gilead-sciences-inc-nasdaqgild-at-risk-of-rejection","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-at-risk-of-rejection-26341","title":{"rendered":"Gilead Sciences, Inc. (NASDAQ:GILD): At Risk Of Rejection"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 06\/19\/2014 (wallstreetpr) \u2013<b> Gilead Sciences, Inc. (NASDAQ:GILD)<\/b> was having the best of times from last some months. But now it seems the real problem for the company is soon going to start. Its Sovaldi treatment is at the risk of rejection from the U.K. Cost Regulators. The regulator has made it clear that it can reject the $60,000 hepatitis C drug treatment. It will look out for details and will then decide over the matter. Accordingly, it will be decided if British government will pay for the treatment or not.<\/p>\n<p style=\"text-align: justify;\"><b>\u00a0The Problem Mounts<\/b><\/p>\n<p style=\"text-align: justify;\">Sovaldi drug treatment got the approval in January. The success rate was as high as 90%. It increased the chances of curing the disease. But recently the news is the effectiveness of drugs is not clearly visible on some patient&#8217;s group. It is a great problem for Gilead Sciences, Inc. (NASDAQ:GILD). It is said by the National Institute for Health and Care Excellence. It has demanded the clear evidences from the company about the cost effectiveness of Sovaldi treatment along with its side effects on the other parts of the body. The company is already facing a lot more problems and oppositions due to the high pricing of Sovaldi treatment. Now it has become imperative for a company to prove that Gilead is a cost effective treatment.<\/p>\n<p style=\"text-align: justify;\"><b>The Company\u2019s View<\/b><\/p>\n<p style=\"text-align: justify;\">Gilead Sciences, Inc. (NASDAQ:GILD) has made it cleared that it would come up with all the evidence requested by the commission. The company is sure to get a positive recommendation. It has got the time till July 4 to come up with the proper evidences. Gilead should make sincere efforts as the effect of the drug is seen on the patients. The medical world needs good drugs, and Sovaldi is becoming one of them. The sales of Sovaldi are expected to cross $9 billion in this year.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 06\/19\/2014 (wallstreetpr) \u2013 Gilead Sciences, Inc. (NASDAQ:GILD) was having the best of times from last some months. But now it seems the real [&hellip;]<\/p>\n","protected":false},"author":10,"featured_media":22073,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[1978,3626,1522],"stock_ticker":[],"class_list":["post-26341","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-gilead-sciences-inc-nasdaqgild","tag-gilead-sciences-inc","tag-nasdaqgild","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Gilead Sciences, Inc. (NASDAQ:GILD): At Risk Of Rejection - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-at-risk-of-rejection-26341\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gilead Sciences, Inc. (NASDAQ:GILD): At Risk Of Rejection - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 06\/19\/2014 (wallstreetpr) \u2013 Gilead Sciences, Inc. (NASDAQ:GILD) was having the best of times from last some months. But now it seems the real [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-at-risk-of-rejection-26341\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-06-19T13:44:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/gilead-sciences.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Alan Masterson\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Alan Masterson\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-at-risk-of-rejection-26341#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-at-risk-of-rejection-26341\"},\"author\":{\"name\":\"Alan Masterson\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90\"},\"headline\":\"Gilead Sciences, Inc. (NASDAQ:GILD): At Risk Of Rejection\",\"datePublished\":\"2014-06-19T13:44:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-at-risk-of-rejection-26341\"},\"wordCount\":320,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-at-risk-of-rejection-26341#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/gilead-sciences.jpg\",\"keywords\":[\"Gilead Sciences Inc (NASDAQ:GILD)\",\"Gilead Sciences Inc.\",\"NASDAQ:GILD\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-at-risk-of-rejection-26341#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-at-risk-of-rejection-26341\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-at-risk-of-rejection-26341\",\"name\":\"Gilead Sciences, Inc. (NASDAQ:GILD): At Risk Of Rejection - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-at-risk-of-rejection-26341#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-at-risk-of-rejection-26341#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/gilead-sciences.jpg\",\"datePublished\":\"2014-06-19T13:44:42+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-at-risk-of-rejection-26341#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-at-risk-of-rejection-26341\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-at-risk-of-rejection-26341#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/gilead-sciences.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/gilead-sciences.jpg\",\"width\":1024,\"height\":380},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-at-risk-of-rejection-26341#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gilead Sciences, Inc. (NASDAQ:GILD): At Risk Of Rejection\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90\",\"name\":\"Alan Masterson\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g\",\"caption\":\"Alan Masterson\"},\"description\":\"Alan has over 25 years of trading experience in the U.S. equity markets. He began his career in finance working on a program trading desk specializing in over-the-counter stocks. His career progressed from that point to his current position as senior trader on an institutional trading desk. In the evenings, Alan teaches economics at a local community college. He has contributed articles to various publications over the last six years, including feature articles for an economics magazine and various financial blogs. You may contact Alan via his email (alanmasterson@cablemanpro.com) or his Google+ page (https:\/\/plus.google.com\/103338576216002376250).\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/alan-masterson\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Gilead Sciences, Inc. (NASDAQ:GILD): At Risk Of Rejection - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-at-risk-of-rejection-26341","og_locale":"en_US","og_type":"article","og_title":"Gilead Sciences, Inc. (NASDAQ:GILD): At Risk Of Rejection - Wall Street PR","og_description":"Boston, MA 06\/19\/2014 (wallstreetpr) \u2013 Gilead Sciences, Inc. (NASDAQ:GILD) was having the best of times from last some months. But now it seems the real [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-at-risk-of-rejection-26341","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-06-19T13:44:42+00:00","og_image":[{"width":1024,"height":380,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/gilead-sciences.jpg","type":"image\/jpeg"}],"author":"Alan Masterson","twitter_misc":{"Written by":"Alan Masterson","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-at-risk-of-rejection-26341#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-at-risk-of-rejection-26341"},"author":{"name":"Alan Masterson","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90"},"headline":"Gilead Sciences, Inc. (NASDAQ:GILD): At Risk Of Rejection","datePublished":"2014-06-19T13:44:42+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-at-risk-of-rejection-26341"},"wordCount":320,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-at-risk-of-rejection-26341#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/gilead-sciences.jpg","keywords":["Gilead Sciences Inc (NASDAQ:GILD)","Gilead Sciences Inc.","NASDAQ:GILD"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-at-risk-of-rejection-26341#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-at-risk-of-rejection-26341","url":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-at-risk-of-rejection-26341","name":"Gilead Sciences, Inc. (NASDAQ:GILD): At Risk Of Rejection - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-at-risk-of-rejection-26341#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-at-risk-of-rejection-26341#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/gilead-sciences.jpg","datePublished":"2014-06-19T13:44:42+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-at-risk-of-rejection-26341#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-at-risk-of-rejection-26341"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-at-risk-of-rejection-26341#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/gilead-sciences.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/gilead-sciences.jpg","width":1024,"height":380},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-at-risk-of-rejection-26341#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Gilead Sciences, Inc. (NASDAQ:GILD): At Risk Of Rejection"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90","name":"Alan Masterson","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g","caption":"Alan Masterson"},"description":"Alan has over 25 years of trading experience in the U.S. equity markets. He began his career in finance working on a program trading desk specializing in over-the-counter stocks. His career progressed from that point to his current position as senior trader on an institutional trading desk. In the evenings, Alan teaches economics at a local community college. He has contributed articles to various publications over the last six years, including feature articles for an economics magazine and various financial blogs. You may contact Alan via his email (alanmasterson@cablemanpro.com) or his Google+ page (https:\/\/plus.google.com\/103338576216002376250).","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/alan-masterson"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/26341","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=26341"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/26341\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/22073"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=26341"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=26341"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=26341"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=26341"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}